Details for New Drug Application (NDA): 050420
✉ Email this page to a colleague
NDA 050420 describes RIFADIN, which is a drug marketed by Sanofi Aventis Us and is included in two NDAs. It is available from one supplier. Additional details are available on the RIFADIN profile page.
The generic ingredient in RIFADIN is rifampin. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.
The generic ingredient in RIFADIN is rifampin. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.
Summary for 050420
| Tradename: | RIFADIN |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | rifampin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050420
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
